Pelthos Therapeutics (PTHS) EBIT Margin (2025 - 2026)

Pelthos Therapeutics (PTHS) posted quarterly EBIT Margin of 72.74% for Q4 2025, up 98.61% quarter-over-quarter from 5225.17% in Q3 2025.

Pelthos Therapeutics (PTHS) EBIT Margin (2025 - 2026) Analysis & Trends

Pelthos Therapeutics' EBIT Margin history runs 1 years deep, the most recent figure standing at 72.74% for Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	138.81 Bn	130.96 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	86.07 Bn	78.08 Bn	3.93 Bn	30.15%
3	Argenx Se	65.47 Bn	60.29 Bn	1.37 Bn	32.54%
4	Moderna	55.64 Bn	50.50 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.99 Bn	36.89 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.68 Bn	28.37 Bn	992.69 Mn	17.93%
7	BioNTech SE	27.69 Bn	9.29 Bn	668.28 Mn	-35.57%
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.36 Bn	26.52 Bn	-	19.75%
10	Pelthos Therapeutics	93.05 Mn	68.49 Mn	21.23 Mn	-114.72%

Download Data